Immunosuppression for the Prevention and Treatment of BOS
Author:
Bhorade Sangeeta M.
Publisher
Springer New York
Reference87 articles.
1. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult lung and heart-lung transplant report—2011. J Heart Lung Transplant. 2011;30(10):1104–22.
2. Wenger RM. Structures of cyclosporine and its metabolites. Transplant Proc. 1990;22:1104–9.
3. Kahan BD. Cyclosporine. N Engl J Med. 1989;321:1725–38.
4. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci. 1994;83:444–6.
5. Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery J, et al. A randomized prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 1996;62:1744–52.